IPO - Silo Pharma, Inc.

Form Type: POS AM

Filing Date: 2025-03-28

Corporate Action: Ipo

Type: New

Accession Number: 000101376225004209

Filing Summary: Silo Pharma, Inc. filed a Post-Effective Amendment to Form S-1 Registration Statement under the Securities Act of 1933. This amendment updates the registration to include the financial statements for the year ending December 31, 2024, filed on the same date. It pertains to the resale of 820,911 shares of common stock issuable upon the exercise of outstanding warrants. The July 2024 Investor Warrants allow for the purchase of 763,638 shares at an exercise price of $2.75, while the July 2024 Placement Agent Warrants allow for purchase of 57,273 shares at $3.4375 per share. The Warrants are immediately exercisable for five years. Anticipated gross proceeds from exercising all Warrants could be approximately $2.3 million. The Company received regulatory approval for its common stock, which trades under the symbol 'SILO' on NASDAQ. The prospectus outlines Silo’s focus on developing novel therapeutics, including psychedelic formulations for PTSD and CNS disorders, and describes its ongoing preclinical studies for several different product candidates, including SPC-15 for PTSD and SP-26 for fibromyalgia. This document serves as an important step in the company's efforts to facilitate investments and capitalize on its intellectual property and clinical developments.

Document Link: View Document